Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Local, but not circulating, complement C3 shapes immune checkpoint blockade efficacy by controlling myeloid cell infiltration.

Nature communications·2026
Same author

PTP1B deficiency in the reward system suppressed the rewarding value of a high-fat diet.

Brain research bulletin·2026
Same author

Dominant T cell receptor clonotypes in adrenocorticotropic hormone-secreting pituitary carcinoma are the highest-frequency clones among CD4<sup>+</sup> and CD8<sup>+</sup> cells in peripheral blood during effective anti-PD-1 therapy.

Frontiers in immunology·2026
Same author

Machine learning-based prediction of impaired arginine vasopressin secretion during hypertonic saline test.

Endocrine journal·2026
Same author

Leveraging a naturally occurring IgM autoantibody to target diabetogenic T cells: a precision medicine approach to type 1 diabetes.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Defining a serum cortisol cutoff level post-CRH stimulation for diagnosing ACTH deficiency: A retrospective study validated by a nationwide registry.

Frontiers in endocrinology·2026

Related Experiment Video

Updated: May 20, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Anatabine ameliorates experimental autoimmune thyroiditis.

Patrizio Caturegli1, Alessandra De Remigis, Marcella Ferlito

  • 1Department of Pathology, Johns Hopkins University School of Medicine, Ross 656, 720 Rutland Avenue, Baltimore, Maryland 21205, USA. pcat@jhmi.edu

Endocrinology
|July 19, 2012
PubMed
Summary

Anatabine, a tobacco alkaloid, shows promise in treating autoimmune thyroiditis. This study found anatabine reduced thyroiditis incidence and severity in mice, suggesting potential therapeutic benefits for thyroid disorders.

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Related Experiment Videos

Last Updated: May 20, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Area of Science:

  • Immunology
  • Endocrinology
  • Pharmacology

Background:

  • Tobacco smoking is linked to a milder course of Hashimoto thyroiditis, potentially due to nicotine's anti-inflammatory effects.
  • Anatabine, a tobacco alkaloid, has anti-inflammatory properties that warrant investigation in autoimmune thyroid conditions.

Purpose of the Study:

  • To evaluate the efficacy of anatabine in a mouse model of experimental autoimmune thyroiditis.
  • To investigate the impact of anatabine on thyroid histopathology, antibody response, thyroid function, and inflammatory gene expression.

Main Methods:

  • Experimental autoimmune thyroiditis was induced in 88 female mice using varying doses of thyroglobulin.
  • Mice received either anatabine-supplemented water or regular water.
  • Assessments included thyroid histopathology, thyroglobulin antibodies, T4 levels, thyroid RNA expression, and in vitro macrophage studies.

Main Results:

  • Anatabine significantly reduced the incidence and severity of thyroiditis in the moderate disease category (62% vs. 96% controls).
  • It decreased antibody responses to thyroglobulin and improved thyroid function recovery.
  • Anatabine suppressed macrophage production of inducible nitric oxide synthase and cyclooxygenase 2.

Conclusions:

  • Anatabine ameliorates experimental autoimmune thyroiditis in mice.
  • Its mechanisms involve reducing inflammation and modulating immune responses.
  • Further research into anatabine's clinical utility for autoimmune thyroid diseases is justified.